Press Releases

PMC press releases highlight the significance of the Coalition’s activities in education, advocacy, and evidence development.


Pace of personalized rare disease treatment approvals more than doubled, from six in 2022 to 16 in 2023
Reflecting its membership from across the health care spectrum, PMC recently elected five new board members from multiple sectors of the health care ecosystem to help guide the future development of its educational, advocacy, and research programs.
The Personalized Medicine Coalition (PMC) is pleased today to welcome congressman John Moolenaar (R-MI-02) as a new co-chair of the Congressional Personalized Medicine Caucus.
Demonstrating PMC's ability to convene executive leaders from across the health care spectrum, PMC today announced that its board of directors has voted to elect three new board members.


Personalized Medicine at FDA: The Scope & Significance of Progress in 2022 Documents Pharmaceutical Industry Shift Away from One-Size-Fits-All Drugs


Cost-Effectiveness Estimates for Infants Less Than a Year Old and Children Under Age 18 May Inform Provider and Payer Practices


PMC President: Newly Approved Treatments and Diagnostic Tools ‘Leave No Question’ About Emergence of Era of Personalized Medicine, Presenting Both Opportunities and Challenges for Patients and Health Systems


Representatives From Change Healthcare, Flatiron Health, and Tempus to Discuss Significance of Paper’s Recommendations at 12:00 p.m. ET


Acknowledging Enhanced Benefits of Multi-Gene Testing, Modernized Definition Could Prompt Changes in Clinical Use of Genomic Sequencing-Based Tests